Laia Adalid-Llansa

Laia Adalid-Llansa

Auto-generated profile, based on publicly available information

Laia Adalid-Llansa

Oncological Pathology and Bioinformatics Research Group, Institut de Recerca Biomèdica Catalunya Sud (IRB CatSud), Tortosa, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2026 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Open access
SAShrief Abdelazeez
Shrief Abdelazeez
FAFaisal Ahmed
Faisal Ahmed
LALaia Adalid
Laia Adalid
KSKrzysztof Siemion
Krzysztof Siemion
CLCarlos López
Carlos López
AKAnna Korzynska
Anna Korzynska
Tumor-infiltrating lymphocytes (TILs) are an important indicator of immune activity in breast cancer, yet scoring them consistently on H&E slides remains challenging in routine pathology. This work presents a modular deep learning pipeline that delivers fully automated and continuous stromal TILs (sTILs) scores in line with the International Immuno-Oncology Biomarker Working Group (IIOBWG) guidelines. The pipeline combines three components: a TIL segmentation model refined through pathologist-guided active learning, a robust stroma segmentation network based on an enhanced DeepLabV3+, and a lightweight regression module that learns how TILs distribute within stromal regions. A new adaptive aggregation strategy integrates patch-level predictions into a single, clinically meaningful score while accounting for heterogeneous infiltration. The system was evaluated on two independent datasets (60 and 112 WSIs) with expert-annotated ROIs, achieving strong agreement with pathologists (Pearson of 0.814; ICC of 0.808). Importantly, the pipeline is interpretable: each stage produces human-readable outputs (stroma masks, TIL-in-stroma maps), and SegGradCAM visualizations confirm that predictions rely on biologically relevant tissue regions. These findings demonstrate the pipeline's potential as a reliable and clinically adaptable tool for standardized, fully automated TILs quantification in breast cancer pathology. The source code and pretrained models are publicly available at https://github.com/Shrief-Abdelazeez/TILs-Scoring.

21 September 2025
Verified
Book Chapter
Closed access
PDF file
LJLauren Jimenez-Martin
Lauren Jimenez-Martin
FVFelip Vilardell
Felip Vilardell
APAna Petit
Ana Petit
EDEduard Dorca
Eduard Dorca
MSM TERESA SOLER-MONSÓ
M TERESA SOLER-MONSÓ
VVVerónica Vilaplana
Verónica Vilaplana

5 October 2024
Verified
Book Chapter
Closed access
PDF file
AFAlessio Fiorin
Alessio Fiorin
LLLaia Adalid Llansa
Laia Adalid Llansa
EGElena Goyda
Elena Goyda
Vincenzo Della MeaVincenzo Della Mea
Vincenzo Della Mea
AKANNA KORZYNSKA
ANNA KORZYNSKA
CLCarlos López
Carlos López

7 March 2026 in Biomedical Signal Processing and Control
Verified
Journal Article
Open access
SAShrief Abdelazeez
Shrief Abdelazeez
AFAlessio Fiorin
Alessio Fiorin
Vincenzo Della MeaVincenzo Della Mea
Vincenzo Della Mea
LALaia Adalid
Laia Adalid
KSKrzysztof Siemion
Krzysztof Siemion
AKAnna Korzynska
Anna Korzynska

3 July 2026 in Breast Cancer Research
Verified
Journal Article
Open access
AFAlessio Fiorin
Alessio Fiorin
LALaia Adalid-Llansa
Laia Adalid-Llansa
LRLaia Reverté
Laia Reverté
ESEsther Sauras-Colón
Esther Sauras-Colón
NGNoèlia Gallardo
Noèlia Gallardo
CLCarlos López
Carlos López
Tumor-infiltrating lymphocytes (TILs) are prognostic biomarkers in breast cancer (BC), particularly in HER2-positive and triple-negative subtypes. Assessment follows the international guidelines, in which pathologists evaluate whole hematoxylin and eosin (H&E)-stained slides while integrating representative regions of the invasive tumor. However, manual region selection can be labor-intensive, subjective, and may introduce variability, particularly across consecutive tissue sections. Automated region of interest (ROI) registration may mitigate this limitation, yet its impact on longitudinal TIL scoring has not been systematically evaluated. Here, we introduce three ROI registration strategies (direct, intermediate, and serial with/without quality control) and present an automated framework validated for consistent TIL scoring and clinical relevance in predicting relapse. We analyzed 104 invasive BC cases, each with 12 consecutive H&E slides. A pathologist annotated ROIs on both the first and twelfth slides. We registered these ROIs using the proposed strategies. We then evaluated them with performance metrics, including Intersection over Union (IoU), Dice Similarity Coefficient (DSC), failure rate, and execution time. Two pathologists scored TILs on manual and automated ROIs. We assessed longitudinal consistency between the first manual ROI and the twelfth slide's corresponding ROIs. We also tested whether the association between TIL score and patient relapse outcomes was preserved. The direct registration strategy achieved the highest geometric accuracy (mean IoU = 0.650, DSC = 0.769), with < 1% failure rate and ∼5.8 s execution time. TIL scores for both manual and automated ROIs closely matched (P = 0.84), showing strong agreement (Spearman's ρ = 0.923, ICC = 0.936, CCC = 0.915, Cohen's κ = 0.786). Longitudinal analyses showed no significant variability across distant sections (P = 0.79 and P = 0.62). TIL concentrations differed significantly between patients with and without relapse, and this association was preserved on both the first and twelfth slides (P < 0.05). We present the first automated framework for longitudinal ROI registration to support TIL scoring in BC. By reducing manual effort and variability, the framework supports scalable evaluation of immune biomarkers across tissue depth while preserving clinically relevant signals, supporting precision immuno-oncology applications.

30 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
LQLaura Quintana Quintana
Laura Quintana Quintana
ESEsther Sauras-Colón
Esther Sauras-Colón
AFAlessio Fiorin
Alessio Fiorin
JSJavier Santana-Nunez
Javier Santana-Nunez
Samuel OrtegaSamuel Ortega
Samuel Ortega
CLCarlos López
Carlos López
Metastasis occurs in nearly 1 out of 3 breast cancer (BC) patients and significantly reduces survival rates, particularly in cases of distant metastases. As most distant metastases develop after diagnosis (i.e., recurrence) and remain incurable, there is a critical need for prognostic biomarkers to assess recurrence risk. Multimodal data analysis has emerged as a promising approach to integrate diverse information, offering a more comprehensive perspective. This study introduces the Histology HSI-BC (hyperspectral imaging - breast cancer) Recurrence Database, the first publicly accessible multimodal database designed to advance BC distant recurrence prediction. The database comprises 47 histopathological whole-slide images, 677 hyperspectral (HS) images, and clinical and demographic data from 47 BC patients, of whom 22 (47%) experienced distant recurrence over a 12-year follow-up. Histopathological slides were digitized using a whole-slide scanner and annotated by expert pathologists, while HS images were acquired with an HS camera coupled to a bright-field microscope. This database provides a promising resource for studying BC recurrence prediction and personalized treatment strategies by integrating the aforementioned multimodal data.